Hepatitis Studies
Shyam Kottilil M.D., Ph.D.Laboratory of Immunoregulation
National Institute of Allergy and InfectiousDiseases
National Institutes of HealthDepartment of Health and Human Services
Bethesda, MD
Hepatitis C and HIV coexist in the US
0
1
2
3
4
5
Num
ber a
ffect
ed (m
illio
ns)
HCV
HIV
Sulkowski MS, Mast EE, Seeff, LB et al. Hepatitis C Virus Infection as an Opportunistic Disease in Persons infected with Human Immunodeficiency Virus. Clin Infect Dis. 2000;30:577-84.
Population
All HIV+
0
20
40
60
80
100
Perc
enta
ge
IVDU90%
33%
Population
Washington, D.C. Our Nation’s Capital
3%=18000 HIV+
1.8%=12000 HCV+
Establishment of Hepatitis Clinics
Average Incidence Rateper 100,000 Population
0 - 25.025.1 – 50.050.1 – 75.075.1 – 100.0100.1 – 125.0
Numbers found below each ward refer to the rate of newly reportedHIV cases per 100,000 population. Rates were calculated using 2000 Census data.
For 16% of cases, ward information was not available and therefore not displayed on this map.
HCV/HIVHCVHIV/HBVHBVHIV/HCV/HBV
Hepatitis Treatment Protocols-DC-PFAP
GS-7977+RBV Anti-fibrosis
Jan Mar Sept Dec Mar JuneJune Sept
HCV DAA Tx
Peg+RBV+PI (Boc) IFN and RBV FREE Tx
TLR7 PHASE 1
Anti-fibrosis
HCV-DAA
HCV-DAA
TLR7 Phase 1Natural History
Anti-fibrosis
Most Effective HIV Program
Most Effective Hepatitis Program
Washington, D.C. Our Nation’s Capital
